There are currently no vaccines with hundred percent efficacy or no effective treatments for lessening hospitalizations brought about by Coronavirus disease 2019 (COVID-19). The influenza vaccination has proposed as a potential method to decrease the seriousness of COVID-19. A prospective cohort study of 37 individuals of Paediatric, Adult and Geriatric group was taken and they were vaccinated against the influenza virus for two consecutive years with the ‘Influenza’ vaccine. Antibody titers were then measured and PCR tests were done to confirm infections. The severity of infection was reflected by hospitalization and emergency unit admission. Examination was performed to analyze the connection between influenza vaccine status and hospitalization. As compared to those who had been vaccinated, COVID-19-positive patients who had not received influenza vaccine during the previous year had a higher risk of hospitalization and ICU admission. Some individuals who were vaccinated for influenza did not even develop any symptoms at all and the others were noticed to have very faint symptom onset. The findings from this study indicate that influenza vaccination can protect against COVID-19 infection in moderate and severe cases. Regardless of comorbidity, this calming influence remains. The literature indicates that RNA interference and natural killer cell activation could be involved.
| Published in | European Journal of Preventive Medicine (Volume 9, Issue 6) |
| DOI | 10.11648/j.ejpm.20210906.15 |
| Page(s) | 162-167 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2021. Published by Science Publishing Group |
COVID-19, Influenza, Vaccine, Vaccination, Efficacy, Coronavirus
| [1] | Adebowale, V., Alderson, D., Burn, W., Dixon, J., Godlee, F., Goddard, A., Griffin, M., Henderson, K., Horton, R., Marshall, M., Martin, J., Morris, E., Nagpaul, C., Rae, M., Rafferty, A. M., & Taylor, J. (2020). Covid-19: Call for a rapid forward looking review of the UK’s preparedness for a second wave -an open letter to the leaders of all UK political parties. In The BMJ (Vol. 369). BMJ Publishing Group. https://doi.org/10.1136/bmj.m2514. |
| [2] | Amato, M., Werba, J. P., Frigerio, B., Coggi, D., Sansaro, D., Ravani, A., Ferrante, P., Veglia, F., Tremoli, E., & Baldassarre, D. (2020). Relationship between Influenza Vaccination Coverage Rate and COVID-19 Outbreak: An Italian Ecological Study. Vaccines, 8 (3), 535. https://doi.org/10.3390/vaccines8030535. |
| [3] | Arokiaraj, M. C. (2020). Correlation of Influenza Vaccination and the COVID-19 Severity. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3572814. |
| [4] | Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D. S. C., Du, B., Li, L., Zeng, G., Yuen, K.-Y., Chen, R., Tang, C., Wang, T., Chen, P., Xiang, J., … Zhong, N. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. New England Journal of Medicine, 382 (18), 1708–1720. https://doi.org/10.1056/NEJMoa2002032. |
| [5] | Gupta, T., & Gupta, S. K. (2020). Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. In International Immunopharmacology (Vol. 86, p. 106717). Elsevier B. V. https://doi.org/10.1016/j.intimp.2020.106717. |
| [6] | Jehi, L., Ji, X., Milinovich, A., Erzurum, S., Rubin, B. P., Gordon, S., Young, J. B., & Kattan, M. W. (2020). Individualizing Risk Prediction for Positive Coronavirus Disease 2019 Testing: Results From 11,672 Patients. Chest, 158 (4), 1364–1375. https://doi.org/10.1016/j.chest.2020.05.580. |
| [7] | Jewett, A. (2020). The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions. Frontiers in Immunology, 11. https://doi.org/10.3389/fimmu.2020.01692. |
| [8] | Paget, J., Caini, S., Cowling, B., Esposito, S., Falsey, A. R., Gentile, A., Kyncl, J., MacIntyre, C., Pitman, R., & Lina, B. (2020). The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies. In Vaccine (Vol. 38, Issue 42, pp. 6485–6486). Elsevier Ltd. https://doi.org/10.1016/j.vaccine.2020.08.024. |
| [9] | Petersen, E., Koopmans, M., Go, U., Hamer, D. H., Petrosillo, N., Castelli, F., Storgaard, M., Al Khalili, S., & Simonsen, L. (2020). Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. In The Lancet Infectious Diseases (Vol. 20, Issue 9, pp. e238–e244). Lancet Publishing Group. https://doi.org/10.1016/S1473-3099(20)30484-9. |
| [10] | Stram, Y., & Kuzntzova, L. (2006). Inhibition of viruses by RNA interference. In Virus Genes (Vol. 32, Issue 3, pp. 299–306). Springer. https://doi.org/10.1007/s11262-005-6914-0. |
| [11] | Tetro, J. A. (2020). Is COVID-19 receiving ADE from other coronaviruses? Microbes and Infection, 22 (2), 72–73. https://doi.org/10.1016/j.micinf.2020.02.006. |
| [12] | Thomas, R. E., Jefferson, T., & Lasserson, T. J. (2013). Influenza vaccination for healthcare workers who care for people aged 60 or older living in long-term care institutions. In Cochrane Database of Systematic Reviews (Vol. 2013, Issue 7). John Wiley and Sons Ltd. https://doi.org/10.1002/14651858.CD005187.pub4. |
| [13] | Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - Journal of the American Medical Association, 323 (11), 1061–1069. https://doi.org/10.1001/jama.2020.1585. |
| [14] | Wise, J. (2020). Covid-19: Risk of second wave is very real, say researchers. BMJ (Clinical Research Ed.), 369, m2294. https://doi.org/10.1136/bmj.m2294. |
| [15] | Worby, C. J., Chaves, S. S., Wallinga, J., Lipsitch, M., Finelli, L., & Goldstein, E. (2015). On the relative role of different age groups in influenza epidemics. Epidemics, 13, 10–16. https://doi.org/10.1016/j.epidem.2015.04.003. |
| [16] | Wu, A., Mihaylova, V. T., Landry, M. L., & Foxman, E. F. (2020). Interference between rhinovirus and influenza A virus: a clinical data analysis and experimental infection study. The Lancet Microbe, 1 (6), e254–e262. https://doi.org/10.1016/s2666-5247(20)30114-2. |
| [17] | Yang, M.-J., Rooks, B. J., Le, T.-T. T., Santiago, I. O., Diamond, J., Dorsey, N. L., & Mainous, A. G. (2021). Influenza Vaccination and Hospitalizations Among COVID-19 Infected Adults. Journal of the American Board of Family Medicine: JABFM, 34 (Suppl), S179–S182. https://doi.org/10.3122/jabfm.2021.S1.200528. |
| [18] | Zanettini, C., Omar, M., Dinalankara, W., Imada, E. L., Colantuoni, E., Parmigiani, G., & Marchionni, L. (2020). Influenza vaccination and COVID19 mortality in the USA. In medRxiv (p. 2020.06.24.20129817). medRxiv. https://doi.org/10.1101/2020.06.24.20129817. |
| [19] | Zhang, W., & Tripp, R. A. (2008). RNA Interference Inhibits Respiratory Syncytial Virus Replication and Disease Pathogenesis without Inhibiting Priming of the Memory Immune Response. Journal of Virology, 82 (24), 12221–12231. https://doi.org/10.1128/jvi.01557-08. |
APA Style
Rahul Anil Sethi, Lalit Hasija, Karine Hakobyan, Armine Hakobyan, Sanobar Shariff, et al. (2021). Efficacy of Influenza Vaccine on Prophylaxis of COVID-19 – a Prospective Cohort Study Done on 37 Patients in Armenia. European Journal of Preventive Medicine, 9(6), 162-167. https://doi.org/10.11648/j.ejpm.20210906.15
ACS Style
Rahul Anil Sethi; Lalit Hasija; Karine Hakobyan; Armine Hakobyan; Sanobar Shariff, et al. Efficacy of Influenza Vaccine on Prophylaxis of COVID-19 – a Prospective Cohort Study Done on 37 Patients in Armenia. Eur. J. Prev. Med. 2021, 9(6), 162-167. doi: 10.11648/j.ejpm.20210906.15
AMA Style
Rahul Anil Sethi, Lalit Hasija, Karine Hakobyan, Armine Hakobyan, Sanobar Shariff, et al. Efficacy of Influenza Vaccine on Prophylaxis of COVID-19 – a Prospective Cohort Study Done on 37 Patients in Armenia. Eur J Prev Med. 2021;9(6):162-167. doi: 10.11648/j.ejpm.20210906.15
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ejpm.20210906.15,
author = {Rahul Anil Sethi and Lalit Hasija and Karine Hakobyan and Armine Hakobyan and Sanobar Shariff and Burhan Kantawala},
title = {Efficacy of Influenza Vaccine on Prophylaxis of COVID-19 – a Prospective Cohort Study Done on 37 Patients in Armenia},
journal = {European Journal of Preventive Medicine},
volume = {9},
number = {6},
pages = {162-167},
doi = {10.11648/j.ejpm.20210906.15},
url = {https://doi.org/10.11648/j.ejpm.20210906.15},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ejpm.20210906.15},
abstract = {There are currently no vaccines with hundred percent efficacy or no effective treatments for lessening hospitalizations brought about by Coronavirus disease 2019 (COVID-19). The influenza vaccination has proposed as a potential method to decrease the seriousness of COVID-19. A prospective cohort study of 37 individuals of Paediatric, Adult and Geriatric group was taken and they were vaccinated against the influenza virus for two consecutive years with the ‘Influenza’ vaccine. Antibody titers were then measured and PCR tests were done to confirm infections. The severity of infection was reflected by hospitalization and emergency unit admission. Examination was performed to analyze the connection between influenza vaccine status and hospitalization. As compared to those who had been vaccinated, COVID-19-positive patients who had not received influenza vaccine during the previous year had a higher risk of hospitalization and ICU admission. Some individuals who were vaccinated for influenza did not even develop any symptoms at all and the others were noticed to have very faint symptom onset. The findings from this study indicate that influenza vaccination can protect against COVID-19 infection in moderate and severe cases. Regardless of comorbidity, this calming influence remains. The literature indicates that RNA interference and natural killer cell activation could be involved.},
year = {2021}
}
TY - JOUR T1 - Efficacy of Influenza Vaccine on Prophylaxis of COVID-19 – a Prospective Cohort Study Done on 37 Patients in Armenia AU - Rahul Anil Sethi AU - Lalit Hasija AU - Karine Hakobyan AU - Armine Hakobyan AU - Sanobar Shariff AU - Burhan Kantawala Y1 - 2021/12/31 PY - 2021 N1 - https://doi.org/10.11648/j.ejpm.20210906.15 DO - 10.11648/j.ejpm.20210906.15 T2 - European Journal of Preventive Medicine JF - European Journal of Preventive Medicine JO - European Journal of Preventive Medicine SP - 162 EP - 167 PB - Science Publishing Group SN - 2330-8230 UR - https://doi.org/10.11648/j.ejpm.20210906.15 AB - There are currently no vaccines with hundred percent efficacy or no effective treatments for lessening hospitalizations brought about by Coronavirus disease 2019 (COVID-19). The influenza vaccination has proposed as a potential method to decrease the seriousness of COVID-19. A prospective cohort study of 37 individuals of Paediatric, Adult and Geriatric group was taken and they were vaccinated against the influenza virus for two consecutive years with the ‘Influenza’ vaccine. Antibody titers were then measured and PCR tests were done to confirm infections. The severity of infection was reflected by hospitalization and emergency unit admission. Examination was performed to analyze the connection between influenza vaccine status and hospitalization. As compared to those who had been vaccinated, COVID-19-positive patients who had not received influenza vaccine during the previous year had a higher risk of hospitalization and ICU admission. Some individuals who were vaccinated for influenza did not even develop any symptoms at all and the others were noticed to have very faint symptom onset. The findings from this study indicate that influenza vaccination can protect against COVID-19 infection in moderate and severe cases. Regardless of comorbidity, this calming influence remains. The literature indicates that RNA interference and natural killer cell activation could be involved. VL - 9 IS - 6 ER -
Email: